According to the latest report by IMARC Group, titled “Needle-free Drug Delivery Technology Market by Product (Inhaler, Jet Injector, Novel Needles, Transdermal Patch, and Others), Application (Vaccine Delivery, Pain Management, Insulin Delivery, and Others), End User (Hospitals and Clinics, Homecare Settings, Research Laboratories, Academics, and Others), and Region 2023-2028,” the global needle-free drug delivery technology market size reached US$ 4.18 Billion in 2022. Needle-free drug delivery technology is a medical innovation that allows for administering medications without using traditional hypodermic needles. It is designed to improve the patient's experience by eliminating the pain and anxiety associated with needle-based injections. Moreover, it aims to reduce the risks of needle-stick injuries and cross-contamination, which are significant concerns in healthcare settings. The technology employs various methods to introduce medications into the body, such as jet injection, which uses high pressure to propel a fine stream of medicine through the skin and into the underlying tissue. Needle-free drug delivery is particularly beneficial for children, geriatric population, and patients fearing needles. It is also valuable in mass vaccination campaigns where quick and efficient delivery of vaccines is essential.
Global Needle-free Drug Delivery Technology Market Trends:
The increasing prevalence of chronic diseases, such as diabetes and cardiovascular conditions necessitating frequent medication administration is one of the major factors contributing to the market growth. Needle-free systems offer a more comfortable and less invasive alternative for patients who require regular injections. In addition to this, the widespread utilization of needle-free drug delivery technology as it addresses critical safety concerns in healthcare and enhances occupational safety is providing a thrust to the market growth. Traditional needle-based systems pose the risk of needle-stick injuries, which can lead to the transmission of infectious diseases among healthcare workers and patients. Along with this, the growing popularity of this technology, as it offers improved patient experience, especially in the pediatric and geriatric population, leading to better compliance with treatment regimens, is creating a positive outlook for the market growth. Moreover, the increasing applicability of needle-free systems in mass immunization programs, enabling faster delivery, which is particularly beneficial in urgent public health situations, such as pandemics or outbreaks, is providing an impetus to the market growth. Furthermore, the increasing regulatory support as governments and healthcare organizations increasingly recognize the benefits of needle-free drug delivery methods by allocating grants and funding for research and development (R&D), thereby facilitating innovation and commercialization, is supporting the market growth. Looking forward, the market value is projected to reach US$ 5.72 Billion by 2028, expanding at a CAGR of 5.22% during 2023-2028.
- Based on the product, the market has been divided into inhaler, jet injector, novel needles, transdermal patch, and others.
- On the basis of the application, the market has been classified into vaccine delivery, pain management, insulin delivery, and others.
- Based on the end user, the market has been categorized into hospitals and clinics, homecare settings, research laboratories, academics, and others.
- Region-wise, the market has been segmented into North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America holds the largest market share.
- The competitive landscape of the market has also been examined, with some of the key players being Akra Dermojet, Antares Pharma Inc. (Halozyme Therapeutics Inc.), Crossject, Mika Medical Co., PharmaJet, Portal Instruments Inc., etc.
|Base Year of the Analysis
||Inhaler, Jet Injector, Novel Needles, Transdermal Patch, Others
||Vaccine Delivery, Pain Management, Insulin Delivery, Others
|End Users Covered
||Hospitals and Clinics, Homecare Settings, Research Laboratories, Academics, Others
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||Akra Dermojet, Antares Pharma Inc. (Halozyme Therapeutics Inc.), Crossject, Mika Medical Co., PharmaJet, Portal Instruments Inc., etc.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800